Replies to post #2272 on Interpace Biosciences Inc. (IDXG)

[Renegades17]

I would worry about Q1 results

Jack spent the bulk of the quarter raising capital and negotiating his way out of the RedPath deal. Did he have enough focus to execute on the business and generate sales? Don't forget, Q4 wasn't very good either given a sharp deceleration in revenue growth.

He will book a gain on the resolution of the severance agreements with the former management team, so that will help some. That said, the benefit from that gain will be spread over 2x the number of shares than he had entering the quarter.

Personally, I would wait for Q1 results or perhaps start nibbling in the low $2s.

[Renegades17]

Getitgogone..what did you think of the numbers?

Revenue growth wasn't stellar, but I expected that given Jack was more focused on capital raising. Burned a lot of cash in the quarter, which isn't good though partly due to one time payments. I won't be surprised if Jack does another capital raise soon given warrant exercises won't happen given they're out of the money.